Publications in collaboration with researchers from Pfizer (United States) (29)

2023

  1. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

    Annals of the rheumatic diseases, Vol. 82, Núm. 5, pp. 698-709

  2. Etanercept Withdrawal and Retreatment in Nonradiographic Axial Spondyloarthritis: Results of RE-EMBARK, an Open-Label Phase IV Trial

    Journal of Rheumatology, Vol. 50, Núm. 4, pp. 478-487

  3. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: Results from the open-label, randomised controlled ORAL Surveillance trial

    Annals of the Rheumatic Diseases, Vol. 82, Núm. 3, pp. 331-343

2022

  1. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

    ACR Open Rheumatology, Vol. 4, Núm. 11, pp. 948-953

  2. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  3. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

    ACR Open Rheumatology, Vol. 4, Núm. 10, pp. 872-882

  4. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by baseline body mass index: an analysis of pooled data from phase 3 studies

    RMD open, Vol. 8, Núm. 1

  5. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  6. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

    RMD Open, Vol. 8, Núm. 2

  7. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2020

  1. Gaps between research and recommendations in rheumatoid arthritis

    Rheumatology International

  2. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis

    Current Therapeutic Research - Clinical and Experimental, Vol. 93

  3. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

  4. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

    Pain, Vol. 161, Núm. 9, pp. 2068-2078

  5. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies

    ACR Open Rheumatology, Vol. 2, Núm. 10, pp. 543-554

2018

  1. Clinical characteristics and patient-reported outcomes in patients with inadequately controlled rheumatoid arthritis despite ongoing treatment

    RMD Open, Vol. 4, Núm. 1

  2. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies

    Rheumatology and Therapy, Vol. 5, Núm. 2, pp. 567-582

  3. Factors influencing the use of biologic therapy and adoption of treat-to-target recommendations in current european rheumatology practice

    Patient Preference and Adherence, Vol. 12, pp. 2007-2014

2017

  1. Exploring the remission concept in rheumatoid arthritis with patients and rheumatologists: Time for a new approach?

    Clinical and Experimental Rheumatology, Vol. 35, Núm. 5, pp. 816-822